Moreover, a phase III study in non-small cell lung cancer (NSCLC) patients revealed increased progression-free survival when radiotherapy was combined with the PD-L1 inhibitor durvalumab compared with the control group (Antonia et al. 2017). This evidence concerns the gene CD274 and non-small cell lung carcinoma.